The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 04, 2021
Filed:
Jul. 24, 2017
Substituted boric acid compound, pharmaceutical composition comprising same, and application thereof
Applicant:
Shenzhen Targetrx, Inc., Guangdong, CN;
Inventors:
Yihan Wang, Shenzhen, CN;
Jiuyang Zhao, Shenzhen, CN;
Assignee:
Shenzhen TargetRx, Inc., Guangdong, CN;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/69 (2006.01); A61K 9/00 (2006.01); C07B 59/00 (2006.01); C07F 5/02 (2006.01); A61P 13/12 (2006.01); A61P 29/00 (2006.01); A61P 35/00 (2006.01); A61P 35/02 (2006.01); A61P 37/00 (2006.01); A61P 9/00 (2006.01); C07K 5/06 (2006.01); C07H 23/00 (2006.01);
U.S. Cl.
CPC ...
C07F 5/02 (2013.01); A61K 31/69 (2013.01); A61P 9/00 (2018.01); A61P 13/12 (2018.01); A61P 29/00 (2018.01); A61P 35/00 (2018.01); A61P 35/02 (2018.01); A61P 37/00 (2018.01); C07B 59/004 (2013.01); C07H 23/00 (2013.01); C07K 5/06 (2013.01); A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); C07B 2200/05 (2013.01);
Abstract
A substituted boric acid compound, a pharmaceutical composition including the same, and an application thereof. The substituted boric acid compound is a compound represented by formula (I), or a crystal form, a pharmaceutically acceptable salt, a prodrug, a stereoisomer, a hydrate, or a solvent compound thereof. The boric acid compound has proteasome inhibitory activity, good pharmacodynamic/pharmacokinetic performance, good applicability, and high safety, and can be used for preparing drugs for treating diseases related to proteasomes.